KRAS and non-small cell lung carcinoma: Using mutant enriched liquid chip (MEL), Zhang has detected EGFR, KRAS, BRAF and PIK3CA in 86 tissue samples and matched plasma samples in NSCLC patients, with overall agreements of 64%, 97%, 98% and 97%, respectively [17].